A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants

Roche

Status and phase: Completed; Phase 1

Conditions: Autistic Disorder; Mental Disorders; Autism Spectrum Disorder; Child Development Disorders, Pervasive; Neurodevelopmental Disorders

Treatments: Drug: RO6953958; Drug: Placebo; Drug: Midazolam

Study type: Interventional

Funder types: Industry

Identifiers

NCT04475848

BP41695

2019-004486-41 (EudraCT Number)

Details and patient eligibility

About

This study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single- and multiple-ascending doses (SAD (Part 1) and MAD (Part 2)) and food effect (FE) of RO6953958 following oral administration in healthy male participants. Part 3 (Drug-drug interaction (DDI)) will assess the safety, tolerability, and effect of RO6953958 on the PK of the cytochrome P450 (CYP) 3A substrate midazolam.

Enrollment: 88 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body mass index (BMI) within 18 to 31 kg/m2
• During treatment and for at least 14 days after the last dose to remain abstinent
• Refrain from donating sperm for at least 14 days after last dose
• Part 2 (MAD) only - Participants must be prepared to collect a sleep log and wear an actigraphy device the week before participation in the study. Participants must also have scored 5 or less on the Pittsburgh Sleep Quality Index (PSQI), less than 13 on the Epworth sleepiness scale (ESS), and not be considered an extreme morning or evening type according to the morningness-eveningness questionnaire (MEQ) at screening to be eligible.

Exclusion criteria

• History or evidence of any medical condition potentially altering the absorption, metabolism, or elimination of drugs
• History of any clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological, or allergic disease, sleep disorders (Part 2 [MAD] only), unexplained syncope (within 12 months prior to screening), metabolic disorder, cancer, or cirrhosis
• Use of any psychoactive medication, or medications known to have effects on central nervous system (CNS), or blood flow
• History of convulsions
• History of clinically significant hypersensitivity (e.g., drugs, excipients) or allergic reactions
• Abnormal blood pressure (BP) and pulse rate
• Presence of orthostatic hypotension
• History or presence of clinically significant ECG abnormalities or cardiovascular disease
• Current or chronic history of liver disease or known hepatic or biliary abnormalities
• Known active or any major episode of infection within 4 weeks prior to the start of drug administration
• Participants who test positive for acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
• Have used or intend to use over-the-counter (OTC) or prescription medication including herbal medications within 30 days prior to dosing
• Positive test for drugs, abuse of alcohol, human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HCV), presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test
• Inability or unwillingness to fully consume standardized breakfast at Day 1
• Part 2 (MAD) only - Participants who have issues sleeping or participants who have travelled across 2 or more time zones in the past month.
• Part 2 (MAD) only - Participants who cannot produce sufficient saliva for study assessments
• Participants who have donated more than 500 mL of blood or blood products or had significant blood loss within 3 months prior to screening
• Have a history of clinically significant back pain, back pathology, and/or back injury that may predispose to complications from, or technical difficulty with, lumbar puncture
• Complications that would lead to difficulty in obtaining a lumbar puncture
• Part 3 (DDI) only - History of hypersensitivity to benzodiazepines (including midazolam) or its formulation ingredients

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

88 participants in 5 patient groups, including a placebo group

Part 1: SAD/FE

Experimental group

Description:

There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of RO6953958 while fasted. Participants in the fed (FE) cohort will return to receive the same single oral dose of RO6953958 repeated in the fed state.

Treatment:

Drug: RO6953958

Part 1: SAD placebo

Placebo Comparator group

Description:

There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of a placebo while fasted/fed.

Treatment:

Drug: Placebo

Part 2: MAD

Experimental group

Description:

A maximum of 5 dose levels are anticipated. For each dose level, a minimum of 8 and a maximum of 16 participants will receive a multiple oral dose of RO6953958 once daily (QD) for 10 days.

Treatment:

Drug: RO6953958

Part 2: MAD placebo

Placebo Comparator group

Description:

A maximum of 5 dose levels are anticipated. For each dose level, a minimum of 8 and a maximum of 16 participants will receive a multiple oral dose of palcebo QD for 10 days.

Treatment:

Drug: Placebo

Part 3: DDI

Experimental group

Description:

RO6953958 will be administered at the maximum dose QD that was tested in the ongoing Part 2 (MAD). Participants will also be administered midazolam.

Treatment:

Drug: Midazolam

Drug: RO6953958